Biomarker, Radiotherapy, Tumor
Conditions
Keywords
Tumor, Radiotherapy, Radioresistance, CHI3L1
Brief summary
Radiotherapy is an important treatment for many malignant tumors. However, radioresistance remains a major cause of treatment failure, often leading to tumor recurrence or progression. As a key factor affecting prognosis, radioresistance currently lacks reliable methods for identifying high-risk individuals before treatment. Liquid biopsy, as a non-invasive and dynamic monitoring tool, offers unique advantages for real-time assessment. Previous studies from our group have shown that peripheral blood levels of CHI3L1 are significantly elevated in patients with radioresistant tumors and may serve as a predictive biomarker for radiotherapy sensitivity. This study aims to conduct a multicenter, bidirectional cohort study to systematically evaluate the predictive value of peripheral blood CHI3L1 as a pan-cancer biomarker for tumor response to radiotherapy.
Interventions
None listed
Sponsors
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Voluntarily signed informed consent form; * Age ≥ 18 years; * No restrictions on sex; * Histologically confirmed diagnosis of one of the following malignant tumors: nasopharyngeal carcinoma, head and neck cancer, lung cancer, breast cancer, gastric cancer, colorectal cancer, glioma, esophageal cancer, liver cancer, cholangiocarcinoma, cervical cancer, prostate cancer, or bladder cancer; * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Exclusion criteria
* Patients with any serious comorbidities that may pose an unacceptable risk or adversely affect compliance with the study protocol. Examples include unstable heart disease requiring treatment, chronic hepatitis, renal disease with poor clinical status, uncontrolled diabetes mellitus (fasting blood glucose \> 1.5 × ULN), or psychiatric disorders. * Deemed unsuitable for participation in the study at the discretion of the investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate（ORR） | Through study completion, up to 3 years | Objective Response Rate (ORR) after Radiotherapy in Tumor Patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Local Control Rate | Through study completion, up to 3 years | Local Control Rate after Radiotherapy in Tumor Patients |
| Local Relapse Free Survival | Through study completion, up to 3 years | Locoregional Recurrence-Free Survival after Radiotherapy in Tumor Patients |
| Progression Free Survival | Through study completion, up to 3 years | Progression-Free Survival after Radiotherapy in Tumor Patients |
| Overall Survival | Through study completion, up to 3 years | Overall Survival after Radiotherapy in Tumor Patients |
Countries
China
Contacts
Primary ContactJian Guan Ph.D.
Outcome results
None listed